189 related articles for article (PubMed ID: 34698359)
1. MicroRNA‑149 inhibits cancer cell malignant phenotype by regulating Akt1 in C4‑2 CRPC cell line.
Zhao J; Li Q; Feng B; Wei D; Han Y; Li M; Wang Y; Luo Y; Jiang Y
Oncol Rep; 2021 Dec; 46(6):. PubMed ID: 34698359
[TBL] [Abstract][Full Text] [Related]
2. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.
Shen T; Wang W; Zhou W; Coleman I; Cai Q; Dong B; Ittmann MM; Creighton CJ; Bian Y; Meng Y; Rowley DR; Nelson PS; Moore DD; Yang F
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586682
[TBL] [Abstract][Full Text] [Related]
3. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
4. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
[TBL] [Abstract][Full Text] [Related]
5. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
[TBL] [Abstract][Full Text] [Related]
6. The roles of microRNAs in the progression of castration-resistant prostate cancer.
Kojima S; Goto Y; Naya Y
J Hum Genet; 2017 Jan; 62(1):25-31. PubMed ID: 27278789
[TBL] [Abstract][Full Text] [Related]
7. Androgen-induced miR-135a acts as a tumor suppressor through downregulating RBAK and MMP11, and mediates resistance to androgen deprivation therapy.
Wan X; Pu H; Huang W; Yang S; Zhang Y; Kong Z; Yang Z; Zhao P; Li A; Li T; Li Y
Oncotarget; 2016 Aug; 7(32):51284-51300. PubMed ID: 27323416
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
[TBL] [Abstract][Full Text] [Related]
9. MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity.
Wang Y; Shao N; Mao X; Zhu M; Fan W; Shen Z; Xiao R; Wang C; Bao W; Xu X; Yang C; Dong J; Yu D; Wu Y; Zhu C; Wen L; Lu X; Lu YJ; Feng N
Oncotarget; 2016 Jul; 7(30):47444-47464. PubMed ID: 27329728
[TBL] [Abstract][Full Text] [Related]
10. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
12. GR silencing impedes the progression of castration-resistant prostate cancer through the JAG1/NOTCH2 pathway via up-regulation of microRNA-143-3p.
Zhang L; Jiang H; Zhang Y; Wang C; Xia X; Sun Y
Cancer Biomark; 2020; 28(4):483-497. PubMed ID: 32568179
[TBL] [Abstract][Full Text] [Related]
13. Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades.
Huang Y; Feng G; Cai J; Peng Q; Yang Z; Yan C; Yang L; Wang Z
Life Sci; 2020 May; 248():117449. PubMed ID: 32088212
[TBL] [Abstract][Full Text] [Related]
14. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
15. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
[TBL] [Abstract][Full Text] [Related]
16. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
17. Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression.
Wan X; Huang W; Yang S; Zhang Y; Zhang P; Kong Z; Li T; Wu H; Jing F; Li Y
Int J Biochem Cell Biol; 2016 Oct; 79():249-260. PubMed ID: 27594411
[TBL] [Abstract][Full Text] [Related]
18. Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.
Zhang A; Lau NA; Wong A; Brown LG; Coleman IM; De Sarkar N; Li D; DeLucia DC; Labrecque MP; Nguyen HM; Conner JL; Dumpit RF; True LD; Lin DW; Corey E; Alumkal JJ; Nelson PS; Morrissey C; Lee JK
Cancer Res Commun; 2023 Nov; 3(11):2358-2374. PubMed ID: 37823778
[TBL] [Abstract][Full Text] [Related]
19. AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways.
Tortorella E; Giantulli S; Sciarra A; Silvestri I
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768370
[TBL] [Abstract][Full Text] [Related]
20. PLCε knockdown enhances the radiosensitivity of castration‑resistant prostate cancer via the AR/PARP1/DNA‑PKcs axis.
Pu J; Li T; Liu N; Luo C; Quan Z; Li L; Wu X
Oncol Rep; 2020 May; 43(5):1397-1412. PubMed ID: 32323799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]